Patients with plaque psoriasis taking apremilast, etanercept, and ustekinumab had a lower rate of serious infections than those who took methotrexate.
Erica Dommasch, MD, MPH
Credit: Beth Israel Deaconess Medical Center
Patients with moderate to severe psoriasis receiving a handful of the newer biologic drugs—apremilast, etanercept, and ustekinumab—had a lower rate of serious infections compared to patients who received methotrexate.
The study also included patients who received the systemic biologics acitretin, adalimumab, and infliximab, who did not have a significant difference in the rate of overall serious infections compared to those who received methotrexate.
Lead author Erica Dommasch, MD, MPH, a dermatologist at Beth Israel Deaconess Medical Center and instructor of dermatology at Harvard Medical School, highlighted the clinical implications of the study results.
"Doctors and patients may want to consider the risks of infection when choosing a systemic treatment for patients with moderate to severe psoriasis," said Dommasch.
The observational cohort study used claims data from 31,595 patients in Optum Clinformatics Data Mart and 76,112 patients in Truven MarketScan from 2003 through 2015. These patients were diagnosed with psoriasis and were new users of acitretin, adalimumab, apremilast, etanercept, infliximab, methotrexate, and ustekinumab.
The study’s primary outcome was serious infection requiring hospitalization, including pneumonia, meningitis/encephalitis, bacteremia/sepsis, cellulitis/soft-tissue infection, endocarditis, pyelonephritis, and septic arthritis/osteoarthritis. Investigators matched via pairwise 1:1 propensity score (PS) to adjust for potential confounders including age, sex, combined comorbidity score, depression, obesity, smoking, and several other factors.
In both claims databases, investigators observed a lower risk of overall serious infections among patients receiving apremilast (hazard ratio [HR], 0.50; 95% CI, 0.26-0.94; P = .03), etanercept (HR, 0.75; 95% CI, 0.61-0.93; P = .01), and ustekinumab (HR, 0.65; 95% CI, 0.47-0.89; P = .01) compared to methotrexate.
There was not a difference in rate of overall serious infections among patients using acitretin, adalimumab, and infliximab compared with methotrexate. However, analysis of the data by type of infection showed that cellulitis was a significantly increased risk for patients using acitretin compared to methotrexate (HR, 1.76; 95% CI, 1.11-2.80; P = .02).
"In addition to being potentially more effective than methotrexate, some of the newer targeted treatments for psoriasis may also be safer for patients in terms of risk of infection," said Dommasch of the study results.
Even newer systemic treatments for plaque psoriasis, such as tildrakizumab (Ilumya) and risankizumab (Skyrizi) were not included in the study as they were approved by the US Food and Drug Administration (FDA) after the study timeframe, in March 2018 and April 2019, respectively.
Dommasch commented that these results should factor into prescribers’ considerations when deciding on therapies for individual patients. "This study demonstrates how researchers can use 'big data' to help compare the safety of different medications for patients with psoriasis," she said.
The study, “Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis,” was published in JAMA Dermatology.